D. Boral Capital analyst Jason Kolbert raised the firm’s price target on Quince Therapeutics (QNCX) to $5 from $4 and keeps a Buy rating on the shares after the company said the last patient has completed their last visit in the pivotal Phase 3 NEAT clinical trial evaluating encapsulated dexamethasone sodium phosphate in patients with Ataxia-Telangiectasia. The firm cites the rolling of its valuation metrics out a year for the target bump.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics announces last visit from last patient in NEAT trial
- Quince Therapeutics publishes summary of early-stage clinical studies of eDSP
- Promising Outlook for Quince Therapeutics: Phase 3 Study and Innovative Platform Drive Buy Recommendation
- Quince Therapeutics Reports Q3 2025 Financial Results
- Quince Therapeutics reports Q3 EPS (25c), consensus (22c)